Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over year

Ascendis Pharma A/S reported financial results for the second quarter ended June 30, 2026, on August 13, 2026. Q2 2026 product revenue reached 315 million, up 105% year over year, comprising 252 million for YORVIPATH, 55 million for SKYTROFA, and 8 million for YUVIWEL.¹ Total revenue for the quarter was 339 million.¹

YORVIPATH (palopegteriparatide, developed as TransCon PTH) revenue totaled 252 million, reflecting consistent new patient demand in the U.S.¹ The company presented 5-year Phase 2 PaTH Forward data at ECE 2026 and 3.5-year Phase 3 PaTHway data at ENDO 2026 showing that long-term treatment with TransCon PTH demonstrated sustained efficacy and safety in adults with hypoparathyroidism.¹

For YUVIWEL (navepegritide, TransCon CNP), more than 220 unique patient enrollments were recorded by more than 100 prescribing healthcare providers, with more than 65% of enrollments approved for reimbursement in the U.S. through July 31, 2026.¹ The company also completed target enrollment for the pivotal reACHin Trial, supporting planned regulatory filings for infants 0 to less than 2 years of age with achondroplasia.¹ Separately, Week 78 data from the COACH Trial of TransCon CNP plus TransCon hGH showed 100% of the 21 enrolled children completed 78 weeks of treatment and remain on therapy.¹

On the balance sheet, the company closed the sale of its Rare Pediatric Disease Priority Review Voucher, awarded upon YUVIWEL's February 2026 FDA approval, to an undisclosed buyer for 158 million in cash, net of transaction-related expenses.¹ Effective May 6, 2026, Ascendis completed redemption of all outstanding $575 million of 2.25% Convertible Senior Notes due 2028, resulting in conversion of all outstanding notes.¹ Cash and cash equivalents as of June 30, 2026 totaled 812 million.¹ Net profit for the quarter was 207 million, or 2.83 per diluted share, compared with a net loss of 39 million a year earlier.¹